B. Riley Has Bullish Outlook for CNTA FY2024 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - B. Riley boosted their FY2024 EPS estimates for shares of Centessa Pharmaceuticals in a research report issued on Tuesday, November 12th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($1.54) for the year, up from their previous estimate of ($1.70). B. Riley currently has a "Buy" rating and a $33.00 target price on the stock. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.68) per share. B. Riley also issued estimates for Centessa Pharmaceuticals' Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.18) EPS.

Other research analysts also recently issued research reports about the stock. Oppenheimer reissued an "outperform" rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Jefferies Financial Group raised their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Finally, Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Trading Down 8.6 %

CNTA traded down $1.50 on Friday, reaching $16.00. 730,621 shares of the company traded hands, compared to its average volume of 404,940. Centessa Pharmaceuticals has a one year low of $5.58 and a one year high of $18.74. The firm has a fifty day simple moving average of $15.90 and a two-hundred day simple moving average of $12.12. The company has a market cap of $1.81 billion, a P/E ratio of -10.46 and a beta of 1.47. The company has a quick ratio of 13.29, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $1,609,000. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $777,000. RTW Investments LP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $800,000. Finally, Point72 Asset Management L.P. increased its position in shares of Centessa Pharmaceuticals by 54.1% during the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after acquiring an additional 953,659 shares during the period. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the sale, the chief executive officer now owns 776,924 shares of the company's stock, valued at $12,834,784.48. This represents a 18.38 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the completion of the sale, the insider now directly owns 206,750 shares of the company's stock, valued at approximately $3,243,907.50. This trade represents a 7.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 325,031 shares of company stock worth $5,213,043. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.